Needham & Company LLC Reaffirms Buy Rating for Liquidia (NASDAQ:LQDA)

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating restated by Needham & Company LLC in a report issued on Thursday,Benzinga reports. They currently have a $19.00 price target on the stock. Needham & Company LLC’s target price points to a potential upside of 85.00% from the stock’s current price.

A number of other research analysts have also weighed in on the company. HC Wainwright reduced their target price on Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. Scotiabank assumed coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock. Lifesci Capital initiated coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective for the company. BTIG Research reduced their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Finally, Bank of America lowered their price target on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Liquidia Stock Down 3.4 %

Shares of NASDAQ:LQDA opened at $10.27 on Thursday. The company has a 50-day moving average price of $10.48 and a two-hundred day moving average price of $11.52. Liquidia has a twelve month low of $6.10 and a twelve month high of $16.99. The firm has a market capitalization of $788.63 million, a PE ratio of -6.54 and a beta of 0.21.

Insider Buying and Selling at Liquidia

In other news, insider Rajeev Saggar sold 2,260 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Liquidia news, General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $28,619.36. Following the transaction, the general counsel now owns 486,048 shares in the company, valued at approximately $5,399,993.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajeev Saggar sold 2,260 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the transaction, the insider now owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,551 shares of company stock worth $236,021. 30.10% of the stock is currently owned by company insiders.

Institutional Trading of Liquidia

Hedge funds have recently modified their holdings of the business. Quest Partners LLC purchased a new stake in Liquidia in the second quarter worth about $27,000. Hilltop National Bank purchased a new stake in shares of Liquidia in the 2nd quarter worth approximately $33,000. Deuterium Capital Management LLC bought a new position in Liquidia during the 2nd quarter valued at approximately $120,000. Clear Harbor Asset Management LLC purchased a new position in Liquidia during the third quarter valued at $100,000. Finally, Signaturefd LLC boosted its holdings in Liquidia by 38,400.0% in the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after acquiring an additional 9,984 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).